Papers - YAMAMOTO Hayato
-
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
Horiguchi H, Hatakeyama S, Yoneyama T, Yoneyama MS, Tanaka T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Yoshizawa T, Hashimoto Y, Kawaguchi T, Ohyama C
Urologic oncology 39 ( 4 ) 238.e9 - 238.e17 2021.4
-
Narrative review of urinary glycan biomarkers in prostate cancer
Shingo Hatakeyama , Tohru Yoneyama , Yuki Tobisawa, Hayato Yamamoto, Chikara Ohyama
Transl Androl Urol 2021.4
-
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma
Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Urol Oncol 2021.4
-
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y, Hatakeyama S, Yoneyama T, Yoneyama MS, Hamano I, Konishi S, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
World journal of urology 2021.3
-
Altered gut microbiome associated with overactive bladder and daily urinary urgency.
Teppei Okamoto, Shingo Hatakeyama, Atsushi Imai, Hayato Yamamoto, Tohru Yoneyama, Kazuyuki Mori, Takahiro Yoneyama, Yasuhiro Hashimoto, Shigeyuki Nakaji, Chikara Ohyama
World journal of urology 39 ( 3 ) 847 - 853 2021.3
-
Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer.
Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
Urologic oncology 39 ( 3 ) 194.e9 - 194.e16 2021.3
-
A Longitudinal Study of Bidirectional Relationships between Sleep Disorder and Frequency of Nocturia: Results from the Iwaki Health Promotion Project
Sakae Konishi, Ohyama Chikara
Urolodia internationalis 2021.3
-
Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy
Fujita Naoki
Urologic oncology 2021.3
-
Altered gut microbiome associated with overactive bladder and daily urinary urgency.
Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C
World journal of urology 39 ( 3 ) 847 - 853 2021.3
-
Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).
Iwamura H, Hatakeyama S, Momota M, Kojima Y, Narita T, Okamoto T, Fujita N, Hamano I, Togashi K, Hamaya T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
Translational andrology and urology 10 ( 3 ) 1143 - 1151 2021.3
-
Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer.
Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C
Urologic oncology 39 ( 3 ) 194.e9 - 194.e16 2021.3
-
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study).
Kodama H, Hatakeyama S, Momota M, Togashi K, Hamaya T, Hamano I, Fujita N, Kojima Y, Okamoto T, Yoneyama T, Yamamoto H, Yoshikawa K, Yoneyama T, Hashimoto Y, Ohyama C
Urologic oncology 39 ( 3 ) 191.e1 - 191.e8 2021.3
-
Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N, Hatakeyama S, Okita K, Momota M, Narita T, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C
Urologic oncology 39 ( 3 ) 191.e9 - 191.e16 2021.3
-
The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study).
Togashi K, Hatakeyama S, Kojima Y, Momota M, Narita T, Iwamura H, Hamano I, Hamaya T, Fujita N, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
Urologic oncology 39 ( 3 ) 192.e7 - 192.e14 2021.3
-
N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.
Kodama H, Yoneyama T, Tanaka T, Noro D, Tobisawa Y, Yamamoto H, Suto S, Hatakeyama S, Mori K, Yoneyama T, Hashimoto Y, Kakizaki I, Nakaji S, Ohyama C
Cancer medicine 10 ( 4 ) 1297 - 1313 2021.2
-
Overactive bladder and sleep disturbance have a significant effect on indoor falls: Results from the community health survey in Japan
Sake Konishi, Ohyama Chikara
lower urinary tract symptoms 2021.1
-
Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer.
Naoki Fujita, Shingo Hatakeyama, Kazutaka Okita, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
Urologic oncology 39 ( 1 ) 75.e9 - 75.e16 2021.1
-
The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan
teppei okamoto, ohyama chikara
world journal of urology 2021.1
-
Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study).
Hamaya T, Hatakeyama S, Momota M, Narita T, Iwamura H, Kojima Y, Hamano I, Fujita N, Okamoto T, Togashi K, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
International journal of clinical oncology 26 ( 1 ) 199 - 206 2021.1
-
The cell surface hyaluronidase TMEM2 regulates cell adhesion and migration via degradation of hyaluronan at focal adhesion sites.
Irie F, Tobisawa Y, Murao A, Yamamoto H, Ohyama C, Yamaguchi Y
The Journal of biological chemistry 296 100481 2021.1